Adapting to thrive in a post-COVID world
Scott Cleve, VP of Regulatory Operations & Compliance at bluebird bio, discusses the following questions and more:
- How did bluebird manage the rapid transition to remote work?
- What changes have there been in interactions with FDA and other health authorities?
- From a regulatory technology standpoint, what changes were needed to facilitate remote working?
- In the new virtual world, how do you see inspection readiness changing?
You can also see the results from the study Scott references, Gens & Assoc. COVID-19 Regulatory Impact, here.
